Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its stake in Vertex Pharmaceuticals by 3.7%, acquiring an additional 1,781 shares during Q2, bringing their total holdings to 50,317 shares valued at approximately $22.4 million.
• Vertex Pharmaceuticals has received mixed reviews from analysts, with target prices ranging from $455.00 to $517.00 and a consensus rating of "Moderate Buy."
• The company's quarterly earnings report showed an EPS of $4.52, surpassing expectations and reflecting an 11.3% increase in revenue year-over-year.

IFM Investors Pty Ltd grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 50,317 shares of the pharmaceutical company's stock after purchasing an additional 1,781 shares during the quarter. IFM Investors Pty Ltd's holdings in Vertex Pharmaceuticals were worth $22,401,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in VRTX. Quent Capital LLC grew its position in shares of Vertex Pharmaceuticals by 4.5% during the 1st quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock worth $249,000 after buying an additional 22 shares during the period. Advisor OS LLC raised its stake in shares of Vertex Pharmaceuticals by 4.4% during the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock worth $263,000 after purchasing an additional 23 shares during the period. Sculati Wealth Management LLC raised its stake in shares of Vertex Pharmaceuticals by 1.0% during the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock worth $1,029,000 after purchasing an additional 25 shares during the period. Avidian Wealth Enterprises LLC grew its holdings in Vertex Pharmaceuticals by 2.1% during the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock valued at $594,000 after buying an additional 25 shares in the last quarter. Finally, Strategic Blueprint LLC grew its holdings in Vertex Pharmaceuticals by 1.7% during the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock valued at $726,000 after buying an additional 25 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs bought 5,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at $17,535,600. This trade represents a 12.50% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

VRTX has been the subject of several recent analyst reports. Cantor Fitzgerald cut their price objective on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Stifel Nicolaus cut their target price on Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating for the company in a research note on Tuesday, August 5th. Morgan Stanley set a $439.00 target price on Vertex Pharmaceuticals and gave the stock an "equal weight" rating in a research note on Tuesday, August 5th. Wells Fargo & Company raised Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 target price for the company in a research note on Wednesday, August 6th. Finally, Canaccord Genuity Group cut their target price on Vertex Pharmaceuticals from $424.00 to $411.00 and set a "hold" rating for the company in a research note on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $496.05.

Vertex Pharmaceuticals Stock Up 0.0%

NASDAQ:VRTX traded up $0.01 on Monday, hitting $383.13. The stock had a trading volume of 1,468,954 shares, compared to its average volume of 1,639,846. The stock has a market cap of $98.23 billion, a price-to-earnings ratio of 27.39 and a beta of 0.44. The business's 50-day simple moving average is $414.44 and its two-hundred day simple moving average is $449.84. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same period last year, the firm earned ($12.83) earnings per share. The company's quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.